SRC and glioblastoma: To date, the most important nTKI is the dual inhibitor c-SRC/Abl (Dasatinib) that was tested alone and in combination with mAb anti-VEGF (Bevacizumab), TKi of EGFR (Erlotinib) and alkylating agent (Lomustine) in clinical trials for recurrent GBM [31,32,33,34].